Tomasz RL

Idioma: Español
Referencias bibliográficas: 10
Paginas: 151-153
Archivo PDF: 31.11 Kb.

RESUMEN

Muchos autores demuestran con ejemplos de sus propios pacientes que la sertralina es una medicación muy eficaz y bien tolerada en el tratamiento de la “depresión mayor” en el curso de las enfermedades de cáncer con metástasis. Presentamos el caso de una entrenadora de gimnasia.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Aguglia E, Casacchia M, Cassano GB. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. International Clinical Psychopharmacology 1993; 8(3): 197-202.

2. Finkel SL, Richter EM, Clary CM. Comparative efficiency and safety of sertraline versus nortriptyline in major depression in patients 70 and older. International Psychogeriatrics 1999; 11(l): 85-99.

3. Keller MB, Gelenberg AJ Hirschfeld RM. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Journal of Clinical Psychiatry 1998; 59(11): 598-607.

4. Keller MB, Harrison W, Fawcett JA. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of under treatment in the community. Psychopharmacology Bulletin 1995; 31(2): 205-12.

5. Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in post psychotic depressive disorder of schizophrenia. Schizophrenia Research 1998; 33: 1-2.

6. Moller HJ, Gallinat J, Hegerl U. Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry 1998; 31(6): 170-7.

7. Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive compulsive disorder. [Review] [72 refs]. Drugs 1992; 44(4): 604-24.

8. Oinan TG. Lithium augmentation in sertraline —resistant depression: a preliminary dose— response study. Psychiatrica Scandinavica 1993; 88(4): 300-1.

9. Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. [Review] [55 refs]. International Clinical Psychopharmacology 1996; 10(3): 129-41.

10. Shapiro PA, Lesperance F, Frasure-Smith N. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction.